| __timestamp | BioMarin Pharmaceutical Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 7751000 |
| Thursday, January 1, 2015 | 402271000 | 10251000 |
| Friday, January 1, 2016 | 476593000 | 9575000 |
| Sunday, January 1, 2017 | 554336000 | 10912000 |
| Monday, January 1, 2018 | 604353000 | 11049000 |
| Tuesday, January 1, 2019 | 680924000 | 11646000 |
| Wednesday, January 1, 2020 | 737669000 | 13265000 |
| Friday, January 1, 2021 | 759375000 | 25805000 |
| Saturday, January 1, 2022 | 854009000 | 35182000 |
| Sunday, January 1, 2023 | 937300000 | 94999000 |
| Monday, January 1, 2024 | 1009025000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc. offer a fascinating contrast in their financial strategies from 2014 to 2023. BioMarin, a leader in the field, has seen its SG&A expenses grow by over 200%, reflecting its expansive operations and market reach. In 2023, BioMarin's expenses peaked at nearly 940 million, a testament to its robust infrastructure and global ambitions.
Conversely, Viridian Therapeutics, a smaller player, has experienced a more modest increase in SG&A expenses, rising from approximately 7.8 million in 2014 to nearly 95 million in 2023. This 12-fold increase highlights Viridian's strategic investments in scaling its operations. As these companies navigate the complexities of the biotech landscape, their financial decisions offer valuable insights into their growth trajectories and market strategies.
Breaking Down SG&A Expenses: GSK plc vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Viridian Therapeutics, Inc.
Xenon Pharmaceuticals Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Xencor, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared